AU2019325565B2 - Anti-Fc epsilon-R1 alpha (FceR1a) antibodies, bispecific antigen-binding molecules that bind FceR1a and CD3, and uses thereof - Google Patents

Anti-Fc epsilon-R1 alpha (FceR1a) antibodies, bispecific antigen-binding molecules that bind FceR1a and CD3, and uses thereof

Info

Publication number
AU2019325565B2
AU2019325565B2 AU2019325565A AU2019325565A AU2019325565B2 AU 2019325565 B2 AU2019325565 B2 AU 2019325565B2 AU 2019325565 A AU2019325565 A AU 2019325565A AU 2019325565 A AU2019325565 A AU 2019325565A AU 2019325565 B2 AU2019325565 B2 AU 2019325565B2
Authority
AU
Australia
Prior art keywords
antigen
amino acid
binding
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019325565A
Other languages
English (en)
Other versions
AU2019325565A1 (en
Inventor
Jee H. Kim
Andre LIMNANDER
Andrew J. Murphy
Jamie M. Orengo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2019325565A1 publication Critical patent/AU2019325565A1/en
Application granted granted Critical
Publication of AU2019325565B2 publication Critical patent/AU2019325565B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2019325565A 2018-08-23 2019-08-22 Anti-Fc epsilon-R1 alpha (FceR1a) antibodies, bispecific antigen-binding molecules that bind FceR1a and CD3, and uses thereof Active AU2019325565B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721921P 2018-08-23 2018-08-23
US62/721,921 2018-08-23
PCT/US2019/047601 WO2020041537A1 (en) 2018-08-23 2019-08-22 Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof

Publications (2)

Publication Number Publication Date
AU2019325565A1 AU2019325565A1 (en) 2021-03-11
AU2019325565B2 true AU2019325565B2 (en) 2025-09-04

Family

ID=67876086

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019325565A Active AU2019325565B2 (en) 2018-08-23 2019-08-22 Anti-Fc epsilon-R1 alpha (FceR1a) antibodies, bispecific antigen-binding molecules that bind FceR1a and CD3, and uses thereof

Country Status (18)

Country Link
US (2) US11578127B2 (enExample)
EP (1) EP3840841A1 (enExample)
JP (2) JP7402223B2 (enExample)
KR (1) KR20210049863A (enExample)
CN (1) CN112888482B (enExample)
AU (1) AU2019325565B2 (enExample)
BR (1) BR112021003023A2 (enExample)
CA (1) CA3109513A1 (enExample)
CL (2) CL2021000437A1 (enExample)
CO (1) CO2021003608A2 (enExample)
EA (1) EA202190601A1 (enExample)
IL (1) IL280745A (enExample)
MX (1) MX2021002165A (enExample)
MY (1) MY204368A (enExample)
PH (1) PH12021550322A1 (enExample)
SG (1) SG11202101608XA (enExample)
WO (1) WO2020041537A1 (enExample)
ZA (1) ZA202100919B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190601A1 (ru) 2018-08-23 2021-07-14 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FCER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FCΕR1Α И CD3, И ИХ ПРИМЕНЕНИЕ
US20230056380A1 (en) * 2020-01-31 2023-02-23 Randy Leiman Allen Methods and kit for detection of analytes
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073142A1 (en) * 2004-09-02 2006-04-06 Genentech, Inc. Anti-Fc-gamma RIIB receptor antibody and uses therefor
US20160039934A1 (en) * 2014-08-07 2016-02-11 Affimed Gmbh Cd3 binding domains
WO2017053856A1 (en) * 2015-09-23 2017-03-30 Regeneron Pharmaceuticals, Inc. Optimized anti-cd3 bispecific antibodies and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
ES2865648T3 (es) 2009-06-26 2021-10-15 Regeneron Pharma Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
WO2012142286A1 (en) * 2011-04-12 2012-10-18 University Of Cincinnati Methods for suppressing allergic reactions
WO2012169741A2 (ko) 2011-06-07 2012-12-13 (주)네오팜 ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CN104293738A (zh) 2013-09-11 2015-01-21 李莉 一种抗人FcεRⅠα亚基单克隆抗体及其应用
CA2957850A1 (en) 2014-08-13 2016-02-18 Suppremol Gmbh Antibodies comprising binding domains to fc.epsilon. receptor (fc.epsilon.r) and fc gamma receptor iib (fc.gamma.riib)
CN104800164B (zh) 2015-04-13 2017-11-07 上海市第一人民医院 一种雷公藤免疫纳米粒及用途
TWI788286B (zh) * 2016-04-13 2023-01-01 法商賽諾菲公司 三特異性和/或三價結合蛋白
EP4273172A3 (en) 2016-09-23 2024-02-28 Regeneron Pharmaceuticals, Inc. Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
EA202190601A1 (ru) 2018-08-23 2021-07-14 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FCER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FCΕR1Α И CD3, И ИХ ПРИМЕНЕНИЕ

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073142A1 (en) * 2004-09-02 2006-04-06 Genentech, Inc. Anti-Fc-gamma RIIB receptor antibody and uses therefor
US20160039934A1 (en) * 2014-08-07 2016-02-11 Affimed Gmbh Cd3 binding domains
WO2017053856A1 (en) * 2015-09-23 2017-03-30 Regeneron Pharmaceuticals, Inc. Optimized anti-cd3 bispecific antibodies and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FRANK RISKE$Q ET AL: "THE JOURNAL OF BIOLOGICAL CHEMISTRY 0 1991 by The American Society for Biochemistry and Molecular Biology, Inc., 15 June 1991, pages 11245 - 11251 *
J. JACKMAN ET AL: "Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 27, 2 July 2010, pages 20850 - 20859. *
JUNG YEON HONG ET AL: "Antibody to Fc[epsilon]RI[alpha] Suppresses Immunoglobulin E Binding to High-Affinity Receptor I in Allergic Inflammation", YONSEI MEDICAL JOURNAL, vol. 57, no. 6, 1 November 2016, pages 1412. *
Turner et al. Signalling through the high-affinity IgE receptor FceRI. Nature |vol. 402 | Supp | Nov. 25, 1999 (Year: 1999). *
Van Lier et al.Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems.Eur. J. Immunol. 1987.17: 1.599-1604 (Year: 1987). *

Also Published As

Publication number Publication date
JP7402223B2 (ja) 2023-12-20
PH12021550322A1 (en) 2021-10-04
MY204368A (en) 2024-08-26
CL2023000442A1 (es) 2023-11-24
AU2019325565A1 (en) 2021-03-11
CN112888482B (zh) 2024-06-25
JP2023171909A (ja) 2023-12-05
ZA202100919B (en) 2025-10-29
EP3840841A1 (en) 2021-06-30
CA3109513A1 (en) 2020-02-27
CO2021003608A2 (es) 2021-04-30
CL2021000437A1 (es) 2021-09-03
JP2021533806A (ja) 2021-12-09
WO2020041537A8 (en) 2020-09-10
US11578127B2 (en) 2023-02-14
NZ772900A (en) 2025-05-02
BR112021003023A2 (pt) 2021-05-11
US20230331845A1 (en) 2023-10-19
MX2021002165A (es) 2021-07-16
CN112888482A (zh) 2021-06-01
JP7541167B2 (ja) 2024-08-27
US12441797B2 (en) 2025-10-14
IL280745A (en) 2021-04-29
SG11202101608XA (en) 2021-03-30
EA202190601A1 (ru) 2021-07-14
WO2020041537A1 (en) 2020-02-27
US20200062844A1 (en) 2020-02-27
KR20210049863A (ko) 2021-05-06

Similar Documents

Publication Publication Date Title
US12252530B2 (en) Human antibodies to Fel d1 and methods of use thereof
AU2019307928B2 (en) Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof
AU2013318059C1 (en) Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof
JP7034068B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
KR20220110510A (ko) 이중특이적 항-BCMA x 항-CD3 항체를 이용한 다발성 골수종의 치료 방법
JP7541167B2 (ja) 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用
EA048275B1 (ru) АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FcER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FcER1A И CD3, И ИХ ПРИМЕНЕНИЕ
EA047227B1 (ru) Биспецифические анти-bcma x анти-cd3 антитела и способы их применения